Quick Answer
Sarepta Therapeutics, Inc. reported Diluted EPS of $7.13 per share (loss) for fiscal year 2025.
Sarepta Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$7.13 | -404.7% |
| 2024 | $2.34 | +140.3% |
| 2023 | -$5.80 | +27.8% |
| 2022 | -$8.03 | -55.9% |
| 2021 | -$5.15 | +27.6% |
| 2020 | -$7.11 | -35450.0% |
| 2011 | -$0.02 | +93.1% |
| 2010 | -$0.29 | -7.4% |
| 2009 | -$0.27 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.80 | -629.4% | -195.2% |
| June 30, 2025 | $1.89 | +2600.0% | +141.1% |
| March 31, 2025 | -$4.60 | -1343.2% | -1452.9% |
| September 30, 2024 | $0.34 | +173.9% | +385.7% |
| June 30, 2024 | $0.07 | +125.9% | -81.1% |
| March 31, 2024 | $0.37 | +106.3% | +180.4% |
| September 30, 2023 | -$0.46 | +84.4% | -70.4% |
| June 30, 2023 | -$0.27 | +89.8% | +95.4% |
- Sarepta Therapeutics, Inc. showed a decrease of -404.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2009–2025 period, Sarepta Therapeutics, Inc.’s diluted eps has declined by 2540.7% (from $0.27 per share (loss) to $7.13 per share (loss)).
- The most recent figure is from Sarepta Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: